Publications

Okhuijsen-Pfeifer C, Huijsman EAH, Hasan A, Sommer IEC, Leucht, S, Kahn RS, Luykx, JJ. Clozapine as a first or second-line treatment in schizophrenia: a systematic review and meta-analysis. Acta Psychiatr Scand. 2018; 138: 281-8. https://onlinelibrary.wiley.com/doi/10.1111/acps.12954

 

Okhuijsen-Pfeifer C, Cohen D, Bogers JPAM, de Vos CMH, Huijsman EAH, Kahn RS, Luykx JJ. Differences between physicians’ and nurse practitioners’ viewpoints on reasons for clozapine underprescription. Brain Behav. 2019; 9: e01318. https://onlinelibrary.wiley.com/doi/10.1002/brb3.1318

 

Okhuijsen-Pfeifer C, Sterk AY, Horn IM, Terstappen J, Kahn RS, Luykx JJ. Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2020; 111: 246-52. https://www.sciencedirect.com/science/article/pii/S0149763419310164?via%3Dihub

 

Okhuijsen-Pfeifer C, Ayhan Y, Lin BD, Van Eijk KR, Bekema E, Kool LJGB, Bogers JPAM, Müderrisoglu A. Babaoglu MO, Van Assche E, Medic J, Veerman S, Cohen D, Van Beek H, De Jonge AAM, Beld E, PAT Clozapine Associated Leukopenia/Agranulocytosis Study Group, Yağcıoğlu AEA, Luykx JJ. Genetic Susceptibility to Clozapine-Induced Agranulocytosis/Neutropenia Across Ethnicities: Results From a New Cohort of Turkish and Other Caucasian Participants, and Meta-Analysis. Schiz Bull Open. 2020; 1: sgaa024. https://academic.oup.com/schizbullopen/article/1/1/sgaa024/5854287

 

Okhuijsen-Pfeifer C, Van der Horst MZ, Bousman CA, Lin BD, Van Eijk KR, Ripke S, Ayhan Y, Babaoglu MO, Bak M, Alink W, Van Beek H, Beld E, Bouhuis A, Edlinger M, Erdogan IM, Ertuğrul A, Yoca G, Everall IP, Görlitz T, GROUP Genetic Risk and Outcome of Psychosis investigators, Grootens KP, Gutwinski S, Hallikainen T, Jeger-Land E, De Koning M, Lähteenvuo M, Legge SE, Leucht S, Morgenroth CL, Müderrisoğlu A, Narang A, Pantelis C, Pardiñas AF, Oviedo-Salcedo T, Schneider-Thoma J, Schreiter S, Repo-Tiihonen E, Tuppurainen H, Veereschild M, Veerman-Bond S, De Vos M, Wagner E, Cohen D, Bogers JPAM, Walters JTR, Yağcıoğlu EA, Tiihonen J, Hasan A, Luykx JJ. Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorder. Preprint MedRxiv. 2021. https://www.medrxiv.org/content/10.1101/2021.06.06.21258200v2

 

Huisman R, Okhuijsen-Pfeifer C, Mulder EYH, Jongkind A, Cohen D, Bogers JPAM, Van der Horst, MZ, Luykx [Validatie van de Nederlandstalige Glasgow Antipsychotica Bijwerkingen Schaal voor Clozapine]. Tijdschr Psychiatr. 2021; 63: 270-5. https://www.tijdschriftvoorpsychiatrie.nl/issues/563/articles/12597

 

Stam N, Taipale H, Tanskanen A, Isphording L, Okhuijsen-Pfeifer C, Schuiling-Veninga CC, Bos JH, Bijker BJ, Tiihonen J., Luykx JJ. Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real-World Study Across Antipsychotics. Clin Transl Sci. 2020; 13: 1170-7. https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.12801

 

Wagner E, Oviedo-Salcedo T, Pelzer N, Strube W, Maurus I. Gutwinski S, Schreiter S, Kleymann P, Morgenroth CL, Okhuijsen-Pfeifer C, Luykx JJ, Schneider-Axmann T, Hasan A. Effects of Smoking Status on Remission and Metabolic and Cognitive Outcomes in Schizophrenia Patients Treated with Clozapine. Pharmacopsych. 2020; 53: 273-83 . https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1208-0045

 

Higgins-Chen AT, Thrush KL, Wang Y, Kuo PL, Wang M, Minteer CJ, Moore AZ, Bandinelli S, Vinkers CH, Vermetten E, Rutten BPF, Geuze E, Okhuijsen-Pfeifer C, Van der Horst MZ, Schreiter S, Gutwinski S, Luykx JJ, Ferrucci L, Crimmins EM, Boks MP, Hägg S, Hu-Seliger TT, Levine ME. A computational solution for bolstering reliability of epigenetic clocks: Implications for clinical trials and longitudinal tracking. Preprint bioRxiv. 2021. https://www.biorxiv.org/content/10.1101/2021.04.16.440205v1